文献速递乳腺MR乳腺X线

影像组学鉴别乳腺癌分子亚型:系统综述与Meta分析

Radiomic differentiation of breast cancer molecular subtypes using pre-operative breast imaging - A systematic review and meta-analysis.
PubMed 文献 · Eur J Radiol · 2021-10-02

MRI影像组学在鉴别HER2+与其他亚型时汇总敏感度0.87、特异度0.88,LABC与其他亚型为0.78/0.83,LBBC与TNBC为0.79/0.88;乳腺X线鉴别TNBC与其他亚型敏感度0.82、特异度0.79。作者认为影像组学是确定分子亚型的新选择,但基因表达检测仍是金标准。

要点

  • MRI影像组学鉴别HER2+与其他亚型汇总敏感度0.87、特异度0.88。
  • MRI鉴别LABC与其他亚型敏感度0.78、特异度0.83;LBBC与TNBC为0.79/0.88。
  • 乳腺X线影像组学鉴别TNBC与其他亚型敏感度0.82、特异度0.79。

核心结论

  • 当代乳腺影像的影像组学肿瘤评估为确定乳腺癌分子亚型提供了新选择,但技术仍需改进,基因表达评估仍是金标准。

研究设计与样本

  • 共10,090例女性患者,平均年龄47.6±11.7岁(范围21-93岁),7,693例报告了分子亚型。
  • Luminal A、Luminal B、HER2过表达型和三阴性乳腺癌分别占51.3%、19.9%、12.3%和16.3%。
  • 研究质量用影像组学质量评分(RQS)评估,提取研究特异性敏感度和特异度进行汇总ROC分析。

诊断标准与关键数值

  • 乳腺X线影像组学鉴别TNBC与其他亚型:汇总敏感度0.82,特异度0.79(7项研究)。
  • MRI影像组学鉴别HER2+与其他亚型:汇总敏感度0.87,特异度0.88。
  • MRI影像组学鉴别LBBC与TNBC:汇总敏感度0.79,特异度0.88。

临床应用与阅片要点

  • 乳腺MRI影像组学对HER2+与其他亚型的鉴别敏感度和特异度较高,可作为无创评估分子亚型的辅助参考。
  • 乳腺X线影像组学对TNBC与其他亚型的鉴别有中等敏感度和特异度,可用于致密型乳腺或MRI不可及时的补充评估。
  • 影像组学结果需结合活检基因表达检测综合判断,不能替代金标准。

局限性

  • 原文未报告各研究的异质性、发表偏倚及影像组学质量评分(RQS)的具体结果。
  • 纳入研究多为回顾性、单中心设计,影像组学特征提取和建模方法差异较大,限制结论外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: Breast cancer has four distinct molecular subtypes which are discriminated using gene expression profiling following biopsy. Radiogenomics is an emerging field which utilises diagnostic imaging to reveal genomic properties of disease. We aimed to perform a systematic review of the current literature to evaluate the value radiomics in differentiating breast cancers into their molecular subtypes using diagnostic imaging.

METHODS: A systematic review was performed as per PRISMA guidelines. Studies assessing radiomictumour analysis in differentiatingbreast cancer molecular subtypeswere included. Quality was assessed using the radiomics quality score (RQS). Diagnostic sensitivity and specificity of radiomic analyses were included for meta-analysis; Study specific sensitivity and specificity were retrieved and summary ROC analysis were performed to compile pooled sensitivities and specificities.

RESULTS: Forty-one studies were included. Overall, there were 10,090 female patients (mean age of 47.6 ± 11.7 years, range: 21-93) and molecular subtypewas reported in 7,693 of cases, with Luminal A (LABC), Luminal B (LBBC), Human Epidermal Growth Factor Receptor-2 overexpressing (HER2+), and Triple Negative (TNBC) breast cancers representing 51.3%, 19.9%, 12.3% and 16.3% of tumour respectively. Seven studies provided radiomic analysis to determine molecular subtypes using mammography to differentiateTNBCvs.others (sensitivity: 0.82,specificity:0.79). Thirty-five studies reported on radiomic analysis of magnetic resonance imaging (MRI); LABC versus others(sensitivity:0.78,specificity:0.83),HER2+versusothers(sensitivity:0.87,specificity:0.88), andLBBCversusTNBC (sensitivity: 0.79,specificity:0.88) respectively.

CONCLUSION: Radiomic tumour assessment of contemporary breast imaging provide a novel option in determining breast cancer molecular subtypes. However, amelioration of such techniques are required and genetic expression assessment will remain the gold standard.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Davey MG, Davey MS, Boland MR, et al. Radiomic differentiation of breast cancer molecular subtypes using pre-operative breast imaging - A systematic review and meta-analysis. Eur J Radiol. 2021. PMID: 34624649. doi:10.1016/j.ejrad.2021.109996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。